MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol will be presented at the American College of Allergy, Asthma and Immunology annual meeting in Philadelphia on November 11 and 12, 2006.
